Comprehensive Functional Self-Antigen Screening to Assess Cross-Reactivity in a Promiscuous Engineered T-cell Receptor
Sharma, G.; Teng, F.; Round, J.; Sneddon, S.; Brown, S.; Sivasothy, S.; Holt, R.
Show abstract
T cell receptor therapeutics are an emerging modality of biologic and cell-based medicines with the unique ability to target intracellular antigens and finely discriminate between healthy and infected or mutated cells. An obstacle to the development of new T cell receptor therapeutics is the difficulty in engineering these proteins for enhanced therapeutic efficacy while avoiding introduction of unexpected off-target autoreactivity. In this study, we apply a functional high-throughput screening assay, Tope-seq, to detecting cross-reactive epitopes in libraries of >5 x 105 unique peptide-coding sequences. We retrospectively analyze an affinity-enhanced engineered T cell receptor, which previously failed clinical trials due to severe off-target toxicity caused by epitope cross-reactivity, by comprehensive functional testing against all genome-coded self-antigens. Using the Tope-seq methodology, we were able to identify the epitope mediating off-target reactivity at a significance threshold of p < 0.01 in first-pass bulk screening. We also identified other potential cross-reactive epitopes of the engineered TCR of-interest, suggesting that the need for assessing promiscuity in TCR based therapeutics is larger than previously appreciated.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- High Throughput pMHC-I Tetramer Library Production Using Chaperone Mediated Peptide Exchange 95%
- Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting 95%
- Isolation of full-length IgG antibodies from combinatorial libraries expressed in the cytoplasm of Escherichia coli 94%
Similar papers in this journal
Similar papers in this journal
- Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals 95%
- A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL) 94%
- An optimized workflow for single-cell transcriptomics and repertoire profiling of purified lymphocytes from clinical samples. 93%
Similar papers in this journal
Similar papers in this journal
- A Simplified Function-First Method for the Discovery and Optimization of Bispecific Immune Engaging Antibodies 95%
- Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant 93%
- A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.